Originalartikel | erschienen - Druck | peer reviewed
Screening for Primary Aldosteronism in Hypertensive Subjects - Results From Two German Epidemiological Studies.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
2012 ;
167(1):
7 - 15
Bibliometrische Indikatoren
Impact Factor = 3,136
Zitierhäufigkeit nach WOS = 89
DOI = 10.1530/EJE-11-1013
PubMed-ID = 22495491
Autoren
Hannemann A*, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Völzke H, Beuschlein F, Seissler J, Rettig R, Felix S, Biffar R, Döring A, Meisinger C, Peters A, Wichmann H, Nauck M, Wallaschofski H, Reincke M
Beteiligte Einrichtungen
Abstract
Objective: The prevalence of primary aldosteronism in unselected hypertensive patients is currently unknown. We investigated the frequency of positive screening results for primary aldosteronism based on the aldosterone-to-renin ratio (ARR) in hypertensive subjects aged 30-79 years from two German epidemiological studies. We further examined the frequency of positive screening results in subjects with resistant hypertension or stage III hypertension and assessed possible disparities between untreated and treated hypertensive subjects.Methods: Data were obtained from the first follow-ups of the population-based Study of Health in Pomerania (SHIP; n=1,392) and the Cooperative Health Research in the Region of Augsburg (KORA; n=1,052). Study-specific reference ranges for plasma aldosterone concentration (PAC), plasma renin concentration (PRC), and the ARR were applied. Confirmation tests for primary aldosteronism were not performed in these epidemiological studies. Three definitions for a positive screening for primary aldosteronism were applied: A) increased ARR; B) increased ARR and decreased PRC; C) increased ARR and increased PAC and decreased PRC.Results: The frequency of positive screening results was 7.0%, 3.8%, and 0.2% according to definitions A-C, respectively. In the subgroups of subjects with resistant hypertension (11.9%, 5.5%, 0.9%) or stage III hypertension (18.3%, 14.0%, 1.1%), these frequencies were markedly higher than those in the general hypertensive population. There was no difference in the frequency of positive screening results between the treated and untreated hypertensive subjects.Conclusions: A maximum of 7.0% of the hypertensive population in Germany shows a positive screening result for primary aldosteronism. Thus, primary aldosteronism may be less frequent than previously expected based on data from referred hypertensive patients.
Veröffentlicht in
EUROPEAN JOURNAL OF ENDOCRINOLOGY
| Jahr | 2012 |
| Impact Factor (2012) | 3,136 |
| Volume | 167 |
| Issue | 1 |
| Seiten | 7 - 15 |
| Open Access | nein |
| Peer reviewed | ja |
| Artikelart | Originalartikel |
| Artikelstatus | erschienen - Druck |
| DOI | 10.1530/EJE-11-1013 |
| PubMed-ID | 22495491 |
Allgemeine Daten zur Fachzeitschrift
Kurzbezeichnung: EUR J ENDOCRINOL
ISSN: 0804-4643
eISSN: 1479-683X
Land: ENGLAND
Sprache: English
Kategorie(n):
Impact Factor Entwicklung
ISSN: 0804-4643
eISSN: 1479-683X
Land: ENGLAND
Sprache: English
Kategorie(n):
- ENDOCRINOLOGY & METABOLISM
Impact Factor Entwicklung
| Jahr | Impact Factor |
|---|---|
| 2008 | 3,791 |
| 2009 | 3,539 |
| 2010 | 3,482 |
| 2011 | 3,423 |
| 2012 | 3,136 |
| 2013 | 3,686 |
| 2014 | 4,069 |
| 2015 | 3,892 |
| 2016 | 4,101 |
| 2017 | 4,333 |
| 2018 | 5,107 |
| 2019 | 5,308 |
| 2020 | 6,664 |
| 2021 | 6,558 |
| 2022 | 5,8 |
| 2023 | 5,3 |
| 2024 | 5,2 |
Projekte
GANI_MED Greifswald Approach to Individualized Medicine (Projektverbund)
FAQs | Impressum | Datenschutz

